The Board of Directors is comprised of

John Clarke, - Managing General Partner, Cardinal Partners; founder of Alkermes and Cubist Pharmaceuticals, founder and chairman of Alnylam

Victor Dzau, M.D. , Chancellor for Health Affairs at Duke University, and President and CEO of the Duke University Health System; James B. Duke Professor of Medicine and Director of Molecular and Genomic Vascular Biology at Duke University

John Maraganore, President and CEO of Alnylam

Vicki L. Sato, Former President and Chief Scientific Officer of Vertex; former Vice President of Research of Biogen, Inc. (now BiogenIdec, Inc.)

Edward Scolnick, M.D, Director of the Psychiatry Initiative at the Broad Institute; former President of Merck Research Laboratories; National Cancer Institute; National Heart Institute

Paul Schimmel, Scripps Institute; founder of Alnylam, Alkermes, Repligen, Cubist; National Academy of Sciences

Phillip Sharp, Institute Professor, MIT Center for Cancer Research; Former Director, McGovern Institute for Brain Research; Nobel Laureate; founder of Biogen and Alnylam; National Academy of Sciences

Kevin Starr, Partner, Third Rock Ventures; Former Chief Operating Officer and Chief Financial Officer of Millennium Pharmaceuticals; former Corporate Controller of Biogen

James L. Vincent, Former Chief Executive Officer and Chairman of Biogen, Inc. (now BiogenIdec, Inc.); Board of Trustees for Duke University